Efficacy and safety of first-line bevacizumab (Bev) combined with paclitaxel (Pac): An observational study in 786 patients (pts) with HER2-negative metastatic breast cancer (mBC).

1079 Background: First-line Bev–Pac is an established treatment option in HER2-negative mBC, significantly improving progression-free survival (PFS) and response rate (RR) versus Pac alone. Two additional trials have demonstrated significantly improved PFS and RR with standard chemotherapy combined with Bev. The ATHENA study confirmed the good tolerability of Bev combined with chemotherapy. In Germany, a non-interventional study evaluated first-line Bev–Pac in the routine oncology practice setting. Methods: Bev–Pac was given according to the European label as first-line therapy to pts with HER2-negative mBC. Safety and efficacy data were collected for up to 1 year (or until progression, death, or Bev discontinuation, if earlier). Results: By Dec 2010, complete data were available for 786 pts. Baseline pt characteristics: median age, 58 years (range 26–87); age ≥65 years, 32%; disease-free interval <1 year, 24%; tumor grade 1/2/3/unknown (%), 2/49/39/5; triple negative, 19%; bone/liver/lung metastases (%),...